Literature DB >> 21893193

Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2.

Seung Bae Rho1, Yong Jung Song, Myong Cheol Lim, Seung-Hoon Lee, Boh-Ram Kim, Sang-Yoon Park.   

Abstract

Programmed cell death 6 (PDCD6) was originally found as a pro-apoptotic protein, but its molecular mechanism is not well understood. In this study, we have attempted to investigate the effects of PDCD6 on the inhibition of angiogenesis-mediated cell growth as a novel anti-angiogenic protein. Purified recombinant human PDCD6 inhibited cell migration in a concentration-time-dependent manner. We also found that overexpressed PDCD6 suppressed vascular endothelial growth factor (VEGF)-induced proliferation, invasion, and capillary-like structure tube formation in vitro. PDCD6 suppressed phosphorylation of signaling regulators downstream from PI3K, including Akt, mammalian target of rapamycin (mTOR), glycogen synthase kinase-3β(GSK-3β), ribosomal protein S6 kinase (p70S6K), and also decreased cyclin D1 expression. We found binding PDCD6 to VEGFR-2, a key player in the PI3K/mTOR/P70S6K signaling pathway. Taken together, these data suggest that PDCD6 plays a significant role in modulating cellular angiogenesis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21893193     DOI: 10.1016/j.cellsig.2011.08.013

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  23 in total

1.  Single nucleotide polymorphisms in PDCD6 gene are associated with the development of cervical squamous cell carcinoma.

Authors:  Bin Zhou; Peng Bai; Hui Xue; Zhu Zhang; Shaoqing Shi; Kui Zhang; Yanyun Wang; Kana Wang; Yi Quan; Yaping Song; Lin Zhang
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

2.  Programmed cell death 6 (PDCD6) as a prognostic marker for gastric cancers.

Authors:  Jung Hwan Yoon; Yoo Jin Choi; Sung Geun Kim; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Tumour Biol       Date:  2011-12-13

Review 3.  Differentiating mTOR inhibitors in renal cell carcinoma.

Authors:  Sumanta K Pal; David I Quinn
Journal:  Cancer Treat Rev       Date:  2013-02-21       Impact factor: 12.111

4.  Prognostic value of PDCD6 polymorphisms and the susceptibility to bladder cancer.

Authors:  Bin Zhou; Peng Zhang; Tielong Tang; Kui Zhang; Yanyun Wang; Yaping Song; Hong Liao; Lin Zhang
Journal:  Tumour Biol       Date:  2014-05-03

5.  Pediatric Ependymoma: A Proteomics Perspective.

Authors:  George Th Tsangaris; Chrissa Papathanasiou; Panagiotis G Adamopoulos; Andreas Scorilas; Constantinos E Vorgias; Neofytos Prodromou; Foteini Tzortzatou Stathopoulou; Dimitrios J Stravopodis; Athanasios K Anagnostopoulos
Journal:  Cancer Genomics Proteomics       Date:  2017 Mar-Apr       Impact factor: 4.069

6.  ALG2 regulates glioblastoma cell proliferation, migration and tumorigenicity.

Authors:  Dunke Zhang; Feng Wang; Yi Pang; Erhu Zhao; Sunqin Zhu; Fei Chen; Hongjuan Cui
Journal:  Biochem Biophys Res Commun       Date:  2017-03-12       Impact factor: 3.575

Review 7.  mTOR Signaling in Kidney Diseases.

Authors:  Yuan Gui; Chunsun Dai
Journal:  Kidney360       Date:  2020-09-03

8.  MicroRNA-183 accelerates the proliferation of hepatocyte during liver regeneration through targeting programmed cell death protein 6.

Authors:  Fangxing Hou; Xing Li; Yanfeng Wang; Xiangzuo Xiao
Journal:  Genes Genomics       Date:  2022-02-21       Impact factor: 2.164

9.  PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer.

Authors:  Dan Su; Haiyan Xu; Jianguo Feng; Yun Gao; Linhui Gu; Lisha Ying; Dionyssios Katsaros; Herbert Yu; Shenhua Xu; Ming Qi
Journal:  J Transl Med       Date:  2012-02-27       Impact factor: 5.531

10.  Structural analysis of the complex between penta-EF-hand ALG-2 protein and Sec31A peptide reveals a novel target recognition mechanism of ALG-2.

Authors:  Takeshi Takahashi; Kyosuke Kojima; Wei Zhang; Kanae Sasaki; Masaru Ito; Hironori Suzuki; Masato Kawasaki; Soichi Wakatsuki; Terunao Takahara; Hideki Shibata; Masatoshi Maki
Journal:  Int J Mol Sci       Date:  2015-02-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.